# Resection of the Primary Tumor vs. Systemic Treatment Alone for Patients With Small Intestinal Neuroendocrine Tumors and Unresectable Metastases: a Europe-wide Study

> **NCT06787014** · — · RECRUITING · sponsor: **Insel Gruppe AG, University Hospital Bern** · enrollment: 3200 (estimated)

## Conditions studied

- Neuroendocrine (NE) Tumors
- Metastasis
- Bowel Obstruction

## Interventions

- **OTHER:** Histopathological review

## Key facts

- **NCT ID:** NCT06787014
- **Lead sponsor:** Insel Gruppe AG, University Hospital Bern
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2026-03-09
- **Primary completion:** 2026-03-09
- **Final completion:** 2028-12-31
- **Target enrollment:** 3200 (ESTIMATED)
- **Last updated:** 2026-03-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06787014

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06787014, "Resection of the Primary Tumor vs. Systemic Treatment Alone for Patients With Small Intestinal Neuroendocrine Tumors and Unresectable Metastases: a Europe-wide Study". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06787014. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*